Sections

Medication

Medication Summary

Eculizumab, a monoclonal antibody that targets C5, is the first drug specifically approved by the US Food and Drug Administration (FDA) for adults with neuromyelitis optica spectrum disorder (NMOSD) who are seropositive for anti-aquaporin-4 (AQP4) antibody.^[15] Inebilizumab, a monoclonal antibody that binds to CD19, and satralizumab, a monoclonal antibody that targets the interleukin-6 (IL-6) receptor, are also approved for treating NMOSD.^{[16, 54, 55]}

Other pharmacologic therapy for optic neuritis (ON) is directed at ameliorating the acute symptoms of pain and decreased vision caused by demyelinating inflammation of the nerve. Varying regimens of corticosteroids have been used for this purpose. A 3-day course of high-dose intravenous (IV) methylprednisolone followed by a rapid oral taper of prednisone has been shown to provide a rapid relief of symptoms in the acute phase. This treatment may also delay the short-term development of multiple sclerosis (MS) after ON; however, IV steroids do little to affect the ultimate visual acuity in patients with ON.

For patients with ON whose brain lesions on magnetic resonance imaging (MRI) indicate a high risk of developing clinically definite MS, treatment with immunomodulators (eg, interferon beta-1a, interferon beta-1b, glatiramer acetate) may be considered.^[17] Intravenous immunoglobulin treatment of acute ON has been shown to have no beneficial effect.

Class Summary

Monoclonal antibodies (eg, eculizumab, inebilizumab, satralizumab) that target aquaporin-4-antibody production or binding have been approved by the FDA for adults with neuromyelitis optica spectrum disorder (NMOSD).

Eculizumab (Soliris)

View full drug information

Monoclonal antibody that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9. The precise mechanism by which eculizumab exerts its therapeutic effect in NMOSD is unknown, but is presumed to involve inhibition of aquaporin-4-antibody–induced terminal complement C5b-9 deposition. It is indicated for adults with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody–positive.

Inebilizumab (Uplizna)

View full drug information

Monoclonal antibody that binds with high affinity to CD19, a protein expressed on a broad range of B cells, including antibody-secreting plasmablasts and plasma cells. After binding to CD19, these cells are rapidly depleted from the circulation. Approximately 80% of patients with NMOSD have autoantibodies to a water channel protein called aquaporin-4 (AQP4). These AQP4-IgG autoantibodies are produced by plasmablasts and plasma cells and bind primarily to astrocytes in the central nervous system. Binding of AQP4-IgG antibodies to CNS cells is believed to trigger attacks, which can damage the optic nerve, spinal cord, and brain.

Satralizumab (Enspryng)

View full drug information

Monoclonal antibody that targets the interleukin 6 (IL-6) receptor. Cytokine IL-6 is thought to be a key cause of NMOSD, triggering the inflammation cascade and leading to damage and disability. It is indicated for NMOSD in adults who are antiaquaporin-4 (AQP4) antibody positive.

Class Summary

These have anti-inflammatory properties and cause profound and varied metabolic effects. In addition, these agents modify the body's immune response to diverse stimuli.

Methylprednisolone (Solu-Medrol, Depo-Medrol, Medrol)

View full drug information

Methylprednisolone is a synthetic corticosteroid used intravenously as an anti-inflammatory and immunosuppressant agent. It has been shown to facilitate the recovery of vision in the acute phase of optic neuritis even though it may not change the long-term visual outcome. In addition, treatment with methylprednisolone may delay the development of MS.

Prednisone

View full drug information

Prednisone may decrease inflammation by reversing increased capillary permeability and suppressing polymorphonuclear (PMN) leukocyte activity. It is a commonly used oral agent. Prednisone is used for an oral taper of steroids, which may reduce the emotional effects of steroid withdrawal and the risk of the development of adrenocortical insufficiency. However, these risks are not very high after only 3 days of treatment with high-dose steroids, and most neurologists do not use a prednisone taper.

Prednisolone (Pediapred, Prelone, Orapred)

View full drug information

Prednisolone may decrease inflammation by reversing increased capillary permeability and suppressing polymorphonuclear (PMN) leukocyte activity. It is a commonly used oral agent. Prednisolone is used for an oral taper of steroids, which may reduce the emotional effects of steroid withdrawal and the risk of the development of adrenocortical insufficiency. However, these risks are not very high after only 3 days of treatment with high-dose steroids, and most neurologists do not use a prednisone taper.

Questions

Beck RW, Smith CH, Gal RL, et al. Neurologic impairment 10 years after optic neuritis. Arch Neurol. 2004 Sep. 61(9):1386-9. [QxMD MEDLINE Link].
Beck RW, Gal RL, Bhatti MT, et al. Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol. 2004 Jan. 137(1):77-83. [QxMD MEDLINE Link].
Atkins EJ, Biousse V, Newman NJ. The natural history of optic neuritis. Rev Neurol Dis. 2006 Spring. 3(2):45-56. [QxMD MEDLINE Link].
Flanagan P, Zele AJ. Chromatic and luminance losses with multiple sclerosis and optic neuritis measured using dynamic random luminance contrast noise. Ophthalmic Physiol Opt. 2004 May. 24(3):225-33. [QxMD MEDLINE Link].
de Stoppelaar JD. [Bacteria as cause of dental caries]. Tijdschr Ziekenverpl. 1975 Nov 18. 28(23):1094-7. [QxMD MEDLINE Link].
Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol. 2007. 6(9):810-815.
Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006 May 23. 66(10):1485-9. [QxMD MEDLINE Link].
Cree B. Neuromyelitis optica: diagnosis, pathogenesis, and treatment. Current Neurology & Neuroscience Reports. Sep/2008. 8(5):427-33.
Kattah JC, Gujrati M. Neuromyelitis optica and autoimmune diseases. Arch Neurol. 2008 Jul. 65(7):995-6; author reply 996. [QxMD MEDLINE Link].
Frederiksen JL, Larsson HB, Henriksen O, Olesen J. Magnetic resonance imaging of the brain in patients with acute monosymptomatic optic neuritis. Acta Neurol Scand. 1989 Dec. 80(6):512-7. [QxMD MEDLINE Link].
CHAMPS Study Group. MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group. Neurology. 2002 Oct 8. 59(7):998-1005. [QxMD MEDLINE Link].
Optic Neuritis Study Group. The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group. Arch Ophthalmol. 1991 Dec. 109(12):1673-8. [QxMD MEDLINE Link].
Optic Neuritis Study Group. Long-term brain magnetic resonance imaging changes after optic neuritis in patients without clinically definite multiple sclerosis. Arch Neurol. 2004 Oct. 61(10):1538-41. [QxMD MEDLINE Link].
Arnold AC. Evolving management of optic neuritis and multiple sclerosis. Am J Ophthalmol. 2005 Jun. 139(6):1101-8. [QxMD MEDLINE Link].
Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, et al. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019 May 3. [QxMD MEDLINE Link].
Cree BAC, Bennett JL, Kim HJ, et al, and the, N-MOmentum study investigators. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019 Oct 12. 394 (10206):1352-1363. [QxMD MEDLINE Link].
Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000 Sep 28. 343(13):898-904. [QxMD MEDLINE Link].
Beck RW. Optic neuritis: Clinical considerations and the relationship to multiple sclerosis. Neuro-ophthalmology. 1998. 20.1-20.3.
Sorensen TL, Frederiksen JL, Bronnum-Hansen H, Petersen HC. Optic neuritis as onset manifestation of multiple sclerosis: a nationwide, long-term survey. Neurology. 1999 Aug 11. 53(3):473-8. [QxMD MEDLINE Link].
Kountakis SE, Maillard AA, Stiernberg CM. Optic neuritis secondary to sphenoethmoiditis: surgical treatment. Am J Otolaryngol. 1995 Nov-Dec. 16(6):422-7. [QxMD MEDLINE Link].
Monteiro ML, Borges WI, do Val Ferreira Ramos C, Lucato LT, Leite CC. Bilateral optic neuritis in wegener granulomatosis. J Neuroophthalmol. 2005 Mar. 25(1):25-8. [QxMD MEDLINE Link].
Nakamoto BK, Dorotheo EU, Biousse V, Tang RA, Schiffman JS, Newman NJ. Progressive outer retinal necrosis presenting with isolated optic neuropathy. Neurology. 2004 Dec 28. 63(12):2423-5. [QxMD MEDLINE Link].
Rush JA, Kennerdell JS, Martinez AJ. Primary idiopathic inflammation of the optic nerve. Am J Ophthalmol. 1982 Mar. 93(3):312-6. [QxMD MEDLINE Link].
Sanborn GE, Kivlin JD, Stevens M. Optic neuritis secondary to sinus disease. Arch Otolaryngol. 1984 Dec. 110(12):816-9. [QxMD MEDLINE Link].
Selbst RG, Selhorst JB, Harbison JW, Myer EC. Parainfectious optic neuritis. Report and review following varicella. Arch Neurol. 1983 Jun. 40(6):347-50. [QxMD MEDLINE Link].
Lee SB, Lee EK, Kim JY. Bilateral optic neuritis in leprosy. Can J Ophthalmol. 2009 Apr. 44(2):219-20. [QxMD MEDLINE Link].
Siddiqui J, Rouleau J, Lee AG, Sato Y, Voigt MD. Bilateral optic neuritis in acute hepatitis C. J Neuroophthalmol. 2009 Jun. 29(2):128-33. [QxMD MEDLINE Link].
Lee HS, Choi KD, Lee JE, Park HK. Optic neuritis after Klebsiella pneumonitis and liver abscess. J Neuroophthalmol. 2009 Jun. 29(2):134-5. [QxMD MEDLINE Link].
Rizzo JF 3rd, Lessell S. Optic neuritis and ischemic optic neuropathy. Overlapping clinical profiles. Arch Ophthalmol. 1991 Dec. 109(12):1668-72. [QxMD MEDLINE Link].
Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005 Aug 15. 202(4):473-7. [QxMD MEDLINE Link].
Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004 Dec 11-17. 364(9451):2106-12. [QxMD MEDLINE Link].
Beck RW, Trobe JD, Moke PS, et al. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol. 2003 Jul. 121(7):944-9. [QxMD MEDLINE Link].
Trobe JD, Sieving PC, Guire KE, Fendrick AM. The impact of the optic neuritis treatment trial on the practices of ophthalmologists and neurologists. Ophthalmology. 1999 Nov. 106(11):2047-53. [QxMD MEDLINE Link].
Lim ET, Grant D, Pashenkov M, Keir G, Thompson EJ, Söderström M, et al. Cerebrospinal fluid levels of brain specific proteins in optic neuritis. Mult Scler. 2004 Jun. 10 (3):261-5. [QxMD MEDLINE Link].
Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol. 2006 Jul. 63(7):964-8. [QxMD MEDLINE Link].
Matsushita T, Isobe N, Matsuoka T, et al. Aquaporin-4 autoimmune syndrome and anti-aquaporin-4 antibody-negative opticospinal multiple sclerosis in Japanese. Mult Scler. 2009 Jul. 15(7):834-47. [QxMD MEDLINE Link].
Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation. 2012 Jan 19. 9(1):14. [QxMD MEDLINE Link].
Koch-Henriksen N, Hyllested K. Epidemiology of multiple sclerosis: incidence and prevalence rates in Denmark 1948-64 based on the Danish Multiple Sclerosis Registry. Acta Neurol Scand. 1988 Nov. 78(5):369-80. [QxMD MEDLINE Link].
Levin LA, Lessell S. Optic neuritis and multiple sclerosis. Arch Ophthalmol. 2003 Jul. 121(7):1039-40. [QxMD MEDLINE Link].
Levin LA, Lessell S. Risk of multiple sclerosis after optic neuritis. JAMA. 2003 Jul 16. 290(3):403-4. [QxMD MEDLINE Link].
Osborne BJ, Volpe NJ. Optic neuritis and risk of MS: differential diagnosis and management. Cleve Clin J Med. 2009 Mar. 76(3):181-90. [QxMD MEDLINE Link].
Takai Y, Misu T, Suzuki H, Takahashi T, Okada H, Tanaka S, et al. Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders. Brain. 2021 Sep 4. 144 (8):2401-2415. [QxMD MEDLINE Link].
Kidd D, Burton B, Plant GT, Graham EM. Chronic relapsing inflammatory optic neuropathy (CRION). Brain. 2003 Feb. 126 (Pt 2):276-84. [QxMD MEDLINE Link]. [Full Text].
Warner JE, Lessell S, Rizzo JF 3rd, Newman NJ. Does optic disc appearance distinguish ischemic optic neuropathy from optic neuritis?. Arch Ophthalmol. 1997 Nov. 115(11):1408-10. [QxMD MEDLINE Link].
Tátrai E, Simó M, Iljicsov A, Németh J, Debuc DC, Somfai GM. In vivo evaluation of retinal neurodegeneration in patients with multiple sclerosis. PLoS One. 2012. 7(1):e30922. [QxMD MEDLINE Link]. [Full Text].
Söderström M, Ya-Ping J, Hillert J, Link H. Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology. 1998 Mar. 50(3):708-14. [QxMD MEDLINE Link].
Cornblath WT, Quint DJ. MRI of optic nerve enlargement in optic neuritis. Neurology. 1997 Apr. 48(4):821-5. [QxMD MEDLINE Link].
Frederiksen JL, Larsson HB, Olesen J. Correlation of magnetic resonance imaging and CSF findings in patients with acute monosymptomatic optic neuritis. Acta Neurol Scand. 1992 Sep. 86(3):317-22. [QxMD MEDLINE Link].
Hickman SJ, Toosy AT, Jones SJ, et al. A serial MRI study following optic nerve mean area in acute optic neuritis. Brain. 2004 Nov. 127:2498-505. [QxMD MEDLINE Link].
Ergene E, Rupp FW Jr, Qualls CR, Ford CC. Acute optic neuritis: association with paranasal sinus inflammatory changes on magnetic resonance imaging. J Neuroimaging. 2000 Oct. 10(4):209-15. [QxMD MEDLINE Link].
Ormerod IE, McDonald WI, du Boulay GH, et al. Disseminated lesions at presentation in patients with optic neuritis. J Neurol Neurosurg Psychiatry. 1986 Feb. 49(2):124-7. [QxMD MEDLINE Link].
Nielsen K, Rostrup E, Frederiksen JL, et al. Magnetic resonance imaging at 3.0 tesla detects more lesions in acute optic neuritis than at 1.5 tesla. Invest Radiol. 2006 Feb. 41(2):76-82. [QxMD MEDLINE Link].
Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol. 2006 Mar. 63(3):390-6. [QxMD MEDLINE Link].
Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, et al. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019 Nov 28. 381 (22):2114-2124. [QxMD MEDLINE Link]. [Full Text].
Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E, Shkrobot S, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020 May. 19 (5):402-412. [QxMD MEDLINE Link].
Diem R, Molnar F, Beisse F, Gross N, Drüschler K, Heinrich SP, et al. Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial-study protocol. BMJ Open. 2016 Mar 1. 6 (3):e010956. [QxMD MEDLINE Link].
Collongues N, de Seze J. An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica. Ther Adv Neurol Disord. 2016 May. 9 (3):180-8. [QxMD MEDLINE Link].
Kim SH, Kim W, Park MS, Sohn EH, Li XF, Kim HJ. Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol. 2011 Apr. 68(4):473-9. [QxMD MEDLINE Link].
Deschamps R, Gueguen A, Parquet N, Saheb S, Driss F, Mesnil M, et al. Plasma exchange response in 34 patients with severe optic neuritis. J Neurol. 2016 May. 263 (5):883-887. [QxMD MEDLINE Link].
Morrow MJ, Ko MW. Should Oral Corticosteroids Be Used to Treat Demyelinating Optic Neuritis?. J Neuroophthalmol. 2017 Dec. 37 (4):444-450. [QxMD MEDLINE Link].
Naumovska M, Sheikh R, Bengtsson B, Malmsjö M, Hammar B. Visual outcome is similar in optic neuritis patients treated with oral and i.v. high-dose methylprednisolone: a retrospective study on 56 patients. BMC Neurol. 2018 Sep 29. 18 (1):160. [QxMD MEDLINE Link].
Watanabe S, Nakashima I, Misu T, Miyazawa I, Shiga Y, Fujihara K. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler. 2007 Jan. 13(1):128-32. [QxMD MEDLINE Link].
Ruprecht K, Klinker E, Dintelmann T, Rieckmann P, Gold R. Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology. 2004 Sep 28. 63(6):1081-3. [QxMD MEDLINE Link].
McKinney AM, Lohman BD, Sarikaya B, Benson M, Benson MT, Lee MS. Accuracy of routine fat-suppressed FLAIR and diffusion-weighted images in detecting clinically evident optic neuritis. Acta Radiol. 2013 Feb 5. [QxMD MEDLINE Link].
Wilhelm H, Schabet M. The Diagnosis and Treatment of Optic Neuritis. Dtsch Arztebl Int. 2015 Sep 11. 112 (37):616-26. [QxMD MEDLINE Link].

Media Gallery

A case of acute optic neuritis. A. 1.5 Tesla, contrast-enhanced spin echo T1-weighted, fat-suppressed coronal MRI through the orbits shows enlargement and contrast enhancement of the left optic nerve in the retrobulbar portion (arrow). B. Coronal spin echo T1-weighted, fat-suppressed MRI of the same patient shows enlargement and contrast enhancement of the nerve in a parasagittal oblique section (arrow).

of 1

Author

Andrew A Dahl, MD, FACS Assistant Professor of Surgery (Ophthalmology), New York College of Medicine (NYCOM); Director of Residency Ophthalmology Training, The Institute for Family Health and Mid-Hudson Family Practice Residency Program; Staff Ophthalmologist, Telluride Medical Center

Andrew A Dahl, MD, FACS is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, American Intraocular Lens Society, American Medical Association, American Society of Cataract and Refractive Surgery, Contact Lens Association of Ophthalmologists, Medical Society of the State of New York, New York State Ophthalmological Society, Outpatient Ophthalmic Surgery Society

Disclosure: Nothing to disclose.

Chief Editor

Edsel B Ing, MD, PhD, MBA, MEd, MPH, MA, FRCSC Professor, Department of Ophthalmology and Vision Sciences, University of Toronto Faculty of Medicine; Staff, Michael Garron Hospital (Toronto East Health Network) and Sunnybrook Hospital, Canada

Edsel B Ing, MD, PhD, MBA, MEd, MPH, MA, FRCSC is a member of the following medical societies: American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Society of Ophthalmic Plastic and Reconstructive Surgery, Canadian Medical Association, Canadian Ophthalmological Society, Canadian Society of Oculoplastic Surgery, Chinese Canadian Medical Society, European Society of Ophthalmic Plastic and Reconstructive Surgery, North American Neuro-Ophthalmology Society, Ontario Medical Association, Royal College of Physicians and Surgeons of Canada, Statistical Society of Canada

Disclosure: Nothing to disclose.

Additional Contributors

Erhan Ergene, MD Clinical Assistant Professor, Department of Neurology, University of Illinois College of Medicine at Peoria; Medical Director, Comprehensive Epilepsy Program and Clinical Neurophysiology, Illinois Neurological Institute at OSF Saint Francis Medical Center

Erhan Ergene, MD is a member of the following medical societies: American Academy of Neurology

Disclosure: Nothing to disclose.

Nancy A Machens, APN, CNP Professor of Nursing, Bradley University; Advanced Practice Nurse, Nurse Practitioner, Department of Neurology, Illinois Neurological Institute at OSF Saint Francis Medical Center

Disclosure: Nothing to disclose.

Reuben M Valenzuela, MD Clinical Assistant Professor of Neurology, Section of Neuro-ophthalmology, Section of Multiple Sclerosis, Illinois Neurological Institute, University of Illinois College of Medicine Peoria; Neurophthalmologist, OSF HealthCare Illinois Neurological Institute

Disclosure: Nothing to disclose.

Acknowledgements

Edsel Ing, MD, FRCSC Associate Professor, Department of Ophthalmology and Vision Sciences, University of Toronto Faculty of Medicine; Consulting Staff, Toronto East General Hospital, Canada

Edsel Ing, MD, FRCSC is a member of the following medical societies: American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Society of Ophthalmic Plastic and Reconstructive Surgery, Canadian Ophthalmological Society, North American Neuro-Ophthalmology Society, and Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

Simon K Law, MD, PharmD Associate Professor of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine

Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, American Glaucoma Society, and Association for Research in Vision and Ophthalmology

Disclosure: Nothing to disclose.

Brian R Younge, MD Professor of Ophthalmology, Mayo Clinic School of Medicine

Brian R Younge, MD is a member of the following medical societies: American Medical Association, American Ophthalmological Society, and North American Neuro-Ophthalmology Society

Disclosure: Nothing to disclose.

Acknowledgments

The authors and editors of Medscape Reference gratefully acknowledge the assistance of Ryan I Huffman, MD, with the literature review and referencing for this article.

Adult Optic Neuritis Medication

Medication Summary

Monoclonal Antibodies